Author:
Sundar Sudha,Wu Jianhua,Hillaby Kathryn,Yap Jason,Lilford Richard
Subject
Obstetrics and Gynaecology,Oncology
Reference16 articles.
1. Guidance for industry clinical trial endpoints for the approval of cancer drugs and biologics;FDA,2007
2. Cyclophosphamide plus cisplatin versus cyclophosphomide, doxorubicin, and cisplatin chemotherapy of ovarian-carcinoma — a metaanalysis;OCMAP;J Clin Oncol,1991
3. Cyclophosphamide plus cisplatin versus cyclophosphomide, doxorubicin, and cisplatin chemotherapy of ovarian-carcinoma — a metaanalysis;OCMAP;Classic Pap Curr Comments,1998
4. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials;Sargent;J Clin Oncol,2005
5. Relationship between effects on time-to-disease progression and overall survival in studies of metastatic breast cancer;Sherrill;Br J Cancer,2008
Cited by
29 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献